MetaVia has released new phase 1 data on DA-1726, an investigational dual agonist targeting GLP-1 and glucagon, highlighting weight loss and metabolic effects in adults with obesity. The update outlines outcomes from an extended dosing cohort and provides additional details on safety, tolerability, and the company’s development plans.
The phase 1 study enrolled adults with obesity who were otherwise healthy. Participants received single and multiple ascending doses of DA-1726, administered once weekly via subcutaneous injection. Each cohort included nine individuals randomized to either four weekly doses of DA-1726 or placebo. The latest findings focus on an extended cohort that was given a fixed, non-titrated 48-mg dose over an eight-week period.
According to MetaVia, participants treated with DA-1726 achieved an average weight loss of 9.1% by Day 54. This represented an increase from the 6.1% reduction observed at Day 26. In parallel with overall weight changes, reductions in waist circumference continued to deepen over time, declining from an average of 5.8 centimeters at Day 26 to 9.8 centimeters at Day 54.
The company also reported effects beyond weight loss. In the same cohort, liver stiffness declined by 23.7%, as measured using a noninvasive ultrasound-based technique. MetaVia is developing DA-1726 for both obesity and metabolic dysfunction-associated steatohepatitis (MASH), and these findings were presented as part of its early clinical assessment.
DA-1726 is entering a field that includes other dual- and multi-agonist therapies. Altimmune has reported mid-phase results for its GLP-1/glucagon dual receptor agonist pemvidutide and plans to advance it into a phase 3 MASH trial. Eli Lilly has also shared phase 3 data in obesity for retatrutide, a triple agonist of GLP-1, glucagon, and GIP.
MetaVia has positioned the balance between GLP-1 and glucagon activity as a distinguishing feature of DA-1726. The company’s candidate uses a three-to-one ratio favoring GLP-1 agonism, compared with pemvidutide’s one-to-one potency ratio. MetaVia has stated that this imbalance is intended to address the glucose-raising effects associated with glucagon agonism, particularly in people with diabetes. In the phase 1 study, fasted glucose levels improved by 12.3 mg/dL from a baseline of 105.3 mg/dL by Day 54.
Safety findings showed no treatment-related discontinuations. Reported gastrointestinal adverse events were described as mild to moderate in severity. Based on these results, MetaVia plans to conduct 16-week studies that will evaluate a single-step titration to 48 mg and a two-step escalation up to a 64-mg dose.
The company has identified rapid titration as a possible advantage relative to existing therapies. Commenting on this approach, MetaVia CEO Hyung Heon Kim said, “Semaglutide, tirzepatide, they’re five steps, meaning it takes six months to go to the optimum dose.”
Following the release of the phase 1 data, MetaVia’s shares opened slightly lower. The company reported a market capitalization of approximately $20 million and ended September with $14.3 million in cash, which it said is sufficient to support operations into 2026. MetaVia has also indicated that it remains open to partnering or licensing its programs.
The promising results from MetaVia’s phase 1 DA‑1726 study build momentum for the company as it prepares for longer and larger trials. The planned 16‑week studies are expected to provide clearer signals on efficacy and safety trends, particularly at higher doses.
In the broader clinical landscape, pharmaceutical companies continue to explore novel mechanisms beyond traditional GLP‑1 receptor agonists. Researchers anticipate that dual agonists like DA‑1726 may offer more comprehensive metabolic benefits, potentially addressing both obesity and liver‑related comorbidities when compared with single‑target therapies.
Investors are watching developments closely, as positive phase 1 data may position MetaVia favorably for strategic partnerships with larger biopharma firms. A successful collaboration could accelerate mid‑stage and late‑stage trials, enhancing the company’s clinical footprint.
Meanwhile, patients and healthcare providers remain keen on new treatment options that offer meaningful weight reduction coupled with improvements in metabolic health. If MetaVia’s DA‑1726 continues to demonstrate safety and efficacy in future studies, it could become a competitive addition to the obesity treatment landscape.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
